|
Mutation Information
|
Mutation Site
|
R263K |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
IN |
|
Relevant Drug
|
tenofovir (TDF);emtricitabine (FTC) |
|
Country
|
US;Thailand |
Literature Information
|
PubMed PMID
|
30951600
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2020 |
|
Journal
|
Journal of the Pediatric Infectious Diseases Society |
|
Title
|
Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study. |
|
Author
|
Viani RM,Ruel T,Alvero C,Fenton T,Acosta EP,Hazra R,Townley E,Palumbo P,Buchanan AM,Vavro C,Singh R,Graham B,Anthony P,George K,Wiznia A,P1093 Study Team . |
|
Evidence
|
HIV-1 genotypic drug resistance testing was available at time of failure from 6 participants;1 had evolution in integrase resistance with E138T, S147G, and R263K mutations at week 192 and phenotypic dolutegravir resistance of a 5.1-fold change.
|
|
|
HIV Mutation Detail Information